ClinicalTrials.gg
TerminatedNCT03638128Updated Dec 20, 2022Results posted

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

A Phase 3 interventional study of Denosumab and Alternative osteoporosis medications in Osteogenesis Imperfecta (OI), sponsored by Amgen. Terminated at 22 sites in 12 countries. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Osteogenesis Imperfecta with a site in United Kingdom — 1 open to participants now, 3 under way, 2 of them phase 3. Osteogenesis Imperfecta · United Kingdom.

Enrollment
8th of 10
75 · median 112
Started
2018
the only one that year
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
3 of 10
Amgen

Among the 10 studies in Osteogenesis Imperfecta with a site in United Kingdom, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 6th registered.

Osteogenesis Imperfecta

84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.

Browse Osteogenesis Imperfecta studies →

Open to participants now

1 of the 10 studies in Osteogenesis Imperfecta with a site in United Kingdom is open now. Recruiting first, the newest first:

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Osteogenesis Imperfecta with a site in United Kingdom, or all of them as a file.
02

Study summary

To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).

Read the detailed description

All participants who completed the prior denosumab study 20130173 (NCT02352753) were offered participation in this study (20170534). Participants could continue to receive denosumab once every 3 months (Q3M) or could receive denosumab once every 6 months (Q6M) or off-treatment observation only at the investigator's discretion. The study design allowed subjects to discontinue denosumab, resume denosumab, initiate alternative osteoporosis medication, discontinue alternative osteoporosis medication, or receive no treatment (observation only) at any time. Therefore results of this study were analyzed according to both baseline treatment and subsequent treatment trajectories.

03

Conditions studied

  • Osteogenesis Imperfecta (OI)

Keywords

  • OI
  • Bone.
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided /assent prior to initiation of any Study 20170534 specific activities/procedures. Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
  • Subject is currently/was enrolled in Study 20130173 and

    • completed the 20130173 End of Study (EOS) visit (regardless of completing or ending product early) OR
    • did not reconsent/reassent to transition to 3-month dosing regimen on Study 20130173 OR
    • early terminated from Study 20130173 as a result of meeting bone mineral density (BMD) Z-score investigational product stopping criteria.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any prohibited proscribed medications while receiving denosumab. Eligibility into study treatment with alternative osteoporosis medication/s of investigator's choice, follow guidelines per the specific alternative osteoporosis medication/s selected. For subjects off-treatment (observation only), no prohibited medications apply.
  • Subjects currently receiving treatment in another device or drug study other than Study 20130173. Other investigational procedures while participating in this study are excluded.
  • For subjects expected to receive investigational product (denosumab) at study day 1: Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 5 months after the last dose of denosumab. Females of (Tanner Stage greater than or equal to 2) should only be included in the study after a negative highly sensitive urine or serum pregnancy test. For study treatment with alternative osteoporosis medication/s of investigator's choice, follow guidelines per the specific alternative osteoporosis medication/s selected. For Subjects off-treatment (observation only), no exclusion applies.
  • For subjects expected to receive investigational product (denosumab) at study day 1: Female subjects of childbearing potential unwilling to practice true sexual abstinence (refrain from heterosexual intercourse) or use 1 highly effective method of during treatment and for an additional 5 months after the last dose of investigational product (denosumab). For study treatment with alternative osteoporosis medication/s of investigator's choice, follow contraception guidelines per the specific alternative osteoporosis medication/s selected. For subjects not receiving any investigational product (observation only), no contraception required.
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Other
    Alternative Medications / Observational

    Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator's discretion and per standard of care and local guidelines.

    Drug: Alternative osteoporosis medications

  • Experimental
    Denosumab 1 mg/kg Q6M

    Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) by subcutaneous injection, but no Q3M denosumab during this study.

    Drug: Denosumab

  • Experimental
    Denosumab 1 mg/kg Q3M

    Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study.

    Drug: Denosumab

Interventions

  • Solution for injection

    Also known as: Prolia

  • DrugAlternative osteoporosis medications

    Alternative osteoporosis medication/s at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest

    A Serious Adverse Event is defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in death (fatal) * Immediately life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event that may have jeopardized the participant or require medical or surgical intervention to prevent 1 of the outcomes listed above. Adverse events of special interest included hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), hypercalcemia, and typical osteogenesis imperfecta (OI) femur fractures.

    Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.

  2. Number of Participants With Anti-denosumab Antibodies

    Blood samples were collected (from denosumab treated participants only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.

    Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months

  3. Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3

    Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.

    Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months

  4. Number of Participants With Clinically Significant Vital Sign Findings

    Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.

    Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months

  5. Number of Participants With Metaphyseal Index Z-score Above Age-appropriate Normal Range

    Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each participant, relative to the participant's age as: MI Z-score = (participant value - mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the participant's age group at the time of the assessment. Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score \> 2.

    Time frame: Baseline, month 12 and month 24

  6. Number of Participants With Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings

    Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if: * A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable). * A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable). Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.

    Time frame: Baseline, month 12, and month 24

  7. Percent Change From Baseline in Mandibular Shaping Parameters

    Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws. The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).

    Time frame: Baseline and month 12 and month 24

Secondary outcomes

  1. Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score

    Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.

    Time frame: Baseline and months 6, 12, and 24

  2. Change From Baseline in Total Hip BMD Z-score

    Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.

    Time frame: Baseline, months 6, 12, and 24

  3. Change From Baseline in Femoral Neck BMD Z-score

    Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.

    Time frame: Baseline and months 6, 12, and 24

07

Results

Posted Dec 20, 2022

Participant flow

This study was conducted at 22 centers in North America, Europe, and Australia from July 2018 to March 2022. The study was an open-label extension of study 20130173 (NCT02352753). Participants who completed the end of study visit or who withdrew consent or assent to transition to every 3 months (Q3M) dosing regimen in Study 20130173 were offered participation in this study.

Participant flow — Overall Study
MilestoneAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Started212727
Completed581
Not completed161926
Withdrew: Withdrawal by subject176
Withdrew: Sponsor decision151219
Withdrew: Lost to follow-up001

Outcome measures

PrimaryNumber of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest

A Serious Adverse Event is defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in death (fatal) * Immediately life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event that may have jeopardized the participant or require medical or surgical intervention to prevent 1 of the outcomes listed above. Adverse events of special interest included hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), hypercalcemia, and typical osteogenesis imperfecta (OI) femur fractures.

Time frame:
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest
ParticipantsAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Any adverse event182219
Serious adverse events656
Adverse events of special interest559
Hypocalcemia001
Hypercalcemia349
Hypersensitivity000
Bacterial cellulitis (skin infection)000
Typical osteogenesis imperfecta femur fractures212
Positively adjudicated osteonecrosis of the jaw000
PrimaryNumber of Participants With Anti-denosumab Antibodies

Blood samples were collected (from denosumab treated participants only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.

Time frame:
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-denosumab Antibodies
ParticipantsDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Anti-denosumab binding antibodies00
Anti-denosumab neutralizing antibodies00
PrimaryNumber of Participants With Clinical Laboratory Toxicities Grade ≥ 3

Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.

Time frame:
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3
ParticipantsAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3000
PrimaryNumber of Participants With Clinically Significant Vital Sign Findings

Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.

Time frame:
From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Findings
ParticipantsAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Number of Participants With Clinically Significant Vital Sign Findings000
PrimaryNumber of Participants With Metaphyseal Index Z-score Above Age-appropriate Normal Range

Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each participant, relative to the participant's age as: MI Z-score = (participant value - mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the participant's age group at the time of the assessment. Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score \> 2.

Time frame:
Baseline, month 12 and month 24
Reported as:
Count of participants · Participants
Number of Participants With Metaphyseal Index Z-score Above Age-appropriate Normal Range
ParticipantsAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Baseline210
Month 12210
Month 2410—
PrimaryNumber of Participants With Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings

Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if: * A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable). * A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable). Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.

Time frame:
Baseline, month 12, and month 24
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings
ParticipantsAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Baseline231
Month 12002
Month 24110
PrimaryPercent Change From Baseline in Mandibular Shaping Parameters

Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws. The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).

Time frame:
Baseline and month 12 and month 24
Reported as:
Mean · percent change
Percent Change From Baseline in Mandibular Shaping Parameters
percent changeAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
Gonial angle: month 120.5 ± 2.4-1.4 ± 1.7-1.0
Gonial angle: month 24-2.1 ± 3.1-1.4 ± 2.2—
SNA angle: month 121.38 ± 2.090.37 ± 2.410.20
SNA angle: month 24-0.07 ± 0.73-1.70 ± 1.79—
SNB angle: month 120.98 ± 1.561.75 ± 2.360.70
SNB angle: month 241.28-1.60 ± 3.18—
ANB angle: month 12-81.06 ± 199.39127.48 ± 312.99-16.26
ANB angle: month 24-79.6915.65 ± 84.75—
SecondaryChange From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score

Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.

Time frame:
Baseline and months 6, 12, and 24
Reported as:
Mean · Z-score
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score
Z-scoreAny Treatment
Month 6-0.11 ± 0.60
Month 12-0.01 ± 0.48
Month 240.21 ± 0.49
SecondaryChange From Baseline in Total Hip BMD Z-score

Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.

Time frame:
Baseline, months 6, 12, and 24
Reported as:
Mean · Z-score
Change From Baseline in Total Hip BMD Z-score
Z-scoreAny Treatment
Month 6-0.07 ± 0.40
Month 120.24 ± 0.42
Month 240.50 ± 0.54
SecondaryChange From Baseline in Femoral Neck BMD Z-score

Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.

Time frame:
Baseline and months 6, 12, and 24
Reported as:
Mean · Z-score
Change From Baseline in Femoral Neck BMD Z-score
Z-scoreAny Treatment
Month 60.08 ± 0.44
Month 120.24 ± 0.39
Month 240.45 ± 0.58

Adverse events

Collected over From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alternative Medications / Observational0/21 (0%)6/21 (28.6%)15/21 (71.4%)
Denosumab 1 mg/kg Q6M0/27 (0%)5/27 (18.5%)21/27 (77.8%)
Denosumab 1 mg/kg Q3M0/27 (0%)6/27 (22.2%)13/27 (48.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
HypercalcaemiaMetabolism and nutrition disorders0/210/275/27
Femur fractureInjury, poisoning and procedural complications2/211/271/27
Forearm fractureInjury, poisoning and procedural complications2/211/270/27
Fibula fractureInjury, poisoning and procedural complications0/212/270/27
Tibia fractureInjury, poisoning and procedural complications0/212/270/27
AppendicitisInfections and infestations1/210/270/27
Lower limb fractureInjury, poisoning and procedural complications1/210/270/27
Ulna fractureInjury, poisoning and procedural complications1/211/270/27
NephrolithiasisRenal and urinary disorders1/211/270/27
AsthmaRespiratory, thoracic and mediastinal disorders1/210/270/27
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAlternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3M
HypercalciuriaRenal and urinary disorders11/2115/271/27
ArthralgiaMusculoskeletal and connective tissue disorders6/217/274/27
Pain in extremityMusculoskeletal and connective tissue disorders3/217/270/27
HypercalcaemiaMetabolism and nutrition disorders3/214/275/27
Back painMusculoskeletal and connective tissue disorders3/214/273/27
HeadacheNervous system disorders3/211/272/27
Abdominal pain upperGastrointestinal disorders2/210/270/27
PyrexiaGeneral disorders0/210/272/27
COVID-19Infections and infestations1/211/272/27
Ankle fractureInjury, poisoning and procedural complications0/210/272/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3MTotal
Mean12.5 ± 3.513.2 ± 2.514.3 ± 4.813.4 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)Alternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3MTotal
Female891330
Male13181445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3MTotal
Hispanic or Latino1034
Not Hispanic or Latino20272471
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alternative Medications / ObservationalDenosumab 1 mg/kg Q6MDenosumab 1 mg/kg Q3MTotal
Asian0011
Black or African American1102
White20252368
Other0112
Multiple0022
08

Study locations

22 sites
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Indiana University - Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • The Childrens Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Perth Childrens Hospital
    Nedlands, Western Australia 6909, Australia
  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
    Bruxelles, 1200, Belgium
  • Childrens Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Shriners Hospital for Children
    Montreal, Quebec H4A 0A9, Canada
  • Fakultni nemocnice Plzen
    Plzen, 305 99, Czechia
  • Thomayerova nemocnice
    Praha 4, 140 59, Czechia
  • Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin
    Bordeaux Cedex, 33076, France
  • Hopital Necker Enfants Malades
    Paris Cedex 15, 75743, France
  • Uniklinik Köln
    Köln, 50931, Germany
  • Semmelweis Egyetem
    Budapest, 1094, Hungary
  • Azienda Ospedaliera Policlinico Umberto I
    Roma, 00161, Italy
  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
    Lodz, 91-738, Poland
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Cataluña 08950, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, Comunidad Valenciana 46026, Spain
  • Birmingham Childrens Hospital
    Birmingham, B4 6NH, United Kingdom
  • Bristol Royal Hospital for Children
    Bristol, BS2 8AE, United Kingdom
  • Royal Hospital for Children
    Glasgow, G51 4TF, United Kingdom
  • Sheffield Childrens Hospital
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Mar 2022, 44 months.

Results were first posted in Dec 2022, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2018
First posted
Aug 20, 2018
StartActual
Jul 26, 2018
Primary completionActual
Mar 28, 2022
CompletionActual
Mar 28, 2022
Results first posted
Dec 20, 2022
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03638128
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Jul 26, 2018
Primary completion
Mar 28, 2022
Completion
Mar 28, 2022
Results posted
Dec 20, 2022
Last update
Dec 20, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion